This high level, multidisciplinary panel will discuss the most recent advances in prostate cancer screening. It will begin with a brief history and background on screening and then move into a presentation on guidelines and controversies based on emerging scientific data. Panelists will then engage in a general discussion followed by Q&A from the audience.

CME and CEU credits are available for medical professionals who attend this session.

Sponsored in part by an Educational Grant from the AdMeTech Foundation and the Massachusetts Department of Public Health
## EDUCATIONAL SESSIONS

### PSA Rising and Clinical Trials
The session will discuss the implications of rising PSA levels after surgery or radiation therapy or even both treatments. PSA doubling time, diagnostic work ups, possible therapeutic modalities and clinical trials will also be discussed.

**Glenn Bubley, MD, Beth Israel Deaconess Medical Center**

### PSA Testing: Shared decision-making
This session will highlight the latest Decision Aid tools developed to help men work with their providers to make informed decisions about PSA testing.

**Mark Kennedy, Executive Director, MPCC**

---

### SAVE THE DATE
**June 24, 2015, 6:00pm**

**Presentation of the Jack Colbert Award to Dr. J. Jacques Carter**

Reception at the Downtown Harvard Club

This year’s recipient is J. Jacques Carter, MD, MPH who is on the staff of the Beth Israel Deaconess Medical Center, an assistant professor at Harvard Medical School, and the medical director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

The Jack Colbert Memorial Award is presented periodically, at the discretion of the MPCC board of directors to a distinguished individual in the medical community who has significantly advanced the fight to conquer and cure prostate cancer through research and/or practice.

Previous recipients of the Jack Colbert Award are:
- 2013 Matthew R. Smith, MD, Ph.D.
- 2011 Richard K. Babayan, MD
- 2010 William U. Shipley, MD
- 2009 Glenn J. Bubley, MD
- 2008 Philip W. Kantoff, MD

---

### Community Perceptions about Prostate Cancer: Creating a sustainable tool for community health
This videotaped panel session will address prevailing perceptions about diagnosis, treatment, recurrence and late stage prostate cancer in communities with predominantly high-risk populations to create a sustainable tool for community health.

**J. Jacques Carter, MD Beth Israel Deaconess Medical Center**

**Aymen Elfiky, MD, Dana-Farber Harvard Cancer Center**

**Mark Kennedy, Executive Director, MPCC**

**Quoc-Dien Trinh, MD, Brigham and Women’s Hospital, Dana-Farber/Harvard Cancer Center**

Moderator: **Christopher Lathan, MD, MS, MPH, Dana-Farber Cancer Institute**

### Imaging Advances in Prostate Cancer
This session will outline the recent advances in MRI that have led to improved detection of clinically significant disease. The session will focus on how these new MRI techniques are applied in patients with prostate cancer and pertinent points on the inherent advantages and limitations will be discussed.

**Mukesh Harisinghani, MD, Massachusetts General Hospital**

### The Inheritability of Prostate Cancer
The session will address family history and ancestry as relates to risk of prostate cancer, and will review recent findings explaining the underlying heritability of risk.

**Mark Pomerantz, MD, Dana-Farber Cancer Institute**

### Quality of Life After Prostate Cancer: Beyond erections
Effective treatments for erectile dysfunction and urinary leakage are available to men after treatment for prostate cancer. However, even after these treatments, some men may experience persistent sexual or urinary problems that affect quality of life. We will discuss strategies to overcome problems with orgasm, urinary leakage during intercourse, and overactive bladder.

**Ravi Kacker, MD, Men’s Health Boston**

### Understanding and Implementing Immunotherapy for Prostate Cancer: Continuing the conversation
A continuation of Dr. Charles Drake’s opening keynote address.
Glenn Bubley, MD, a member of the MPCC Medical Advisory Committee, has been the director of a multidisciplinary genitourinary cancer program dealing primarily with prostate biology at the Beth Israel Deaconess Medical Center since 1988. In 2009, MPCC honored him with the Jack Colbert Award.

J. Jacques Carter, MD is the medical director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute and is an assistant professor of medicine at Harvard Medical School. He is the 2015 recipient of MPCC’s Jack Colbert Memorial Award.

Charles Drake, MD is associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine and the co-director of the Prostate Cancer Multidisciplinary Clinic.

Aymen Elfiky, MD, MA, MPH is a medical oncologist and instructor in medicine at Harvard Medical School. He is affiliated with the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Mukesh G. Harisinghani, MD is director of abdominal MRI at Massachusetts General Hospital and professor of radiology at Harvard Medical School.

Ravi Kacker, MD is a urologist and clinical instructor at Harvard Medical School. He is on the staff of Men’s Health Boston and a part-time instructor in surgery at Beth Israel Deaconess Medical Center.

Mark Kennedy, MBA is the executive director of the Massachusetts Prostate Cancer Coalition. Previously he served as manager of Men’s Health Programs for Dana-Farber’s Community Benefits Office. Working with healthcare providers, Kennedy delivered prostate cancer educational interventions and is developing prostate cancer clinical practice guidance to standardize service protocols for high-risk men.

Neal Martin, MD is assistant professor of radiation oncology at Harvard Medical School and the Dana-Farber/Brigham and Women’s Cancer Center. His research has focused on molecular markers related to prognosis and prediction for prostate cancer.

Mark Pomerantz, MD is a medical oncologist at the Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.

Faina Shtern, MD is the president and CEO of AdMeTech, whose mission is to provide unique and critically needed international leadership for expediting the development and implementation of advanced diagnostic tools for improved prevention, early detection and treatment of prostate cancer.

Quoc-Dien Trinh, MD is assistant professor of surgery at Harvard Medical School and is affiliated with the Dana-Farber Cancer Institute and with the Center for Surgery and Public Health at Brigham and Women’s Hospital.

Andrew Vickers, Ph.D. is attending research methodologist at Memorial Sloan Kettering Cancer Center. His research falls into three broad areas: randomized trials, surgical outcomes research and molecular marker studies. A particular focus of his work is the detection and initial treatment of prostate cancer.

Many thanks to this year’s generous sponsors.

Massachusetts Department of Public Health
Massachusetts Prostate Cancer Coalition
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
The Barron Center for Men’s Health — Mount Auburn Hospital
Peter Lacallaide
Allen Snyder
Hall Swaim
Robert Kretschmar
Kirk Neison
Avi Nelson
Garth Greimann

The exhibitors provide an array of pertinent information on prostate cancer resources. Please visit each table to learn about the medical and on-going support systems available.

AdMeTech Foundation
American Cancer Society
Beth Israel Deaconess Medical Center
Boston Prostate Cancer Walk
Cancer Support Community – Massachusetts South Shore
Janssen Biotech, Inc.
Massachusetts Prostate Cancer Coalition
Prostate Health Education Network
# SYMPOSIUM PLANNING COMMITTEE

- Lynn A. Basilio
- American Cancer Society
- Anita Christie
- Massachusetts Department of Public Health
- Thomas L. Farmer
- Judy Green
- Massachusetts Prostate Cancer Coalition
- Mark Kennedy
- Massachusetts Prostate Cancer Coalition
- Jane Matlaw
- Beth Israel Deaconess Medical Center
- Tiffany Nagle
- Cullari Communications Global
- Dalton A. Skerritt
- Center for the Elimination of Health and Social Inequities and Disparities (CEHSID)
- Matthew R. Smith, MD
- Massachusetts General Hospital
- Allen L. Snyder III
- Northwestern Mutual Life Financial Network
- C. Hall Swaim
- WilmerHale LLP
- William Tinney

# BOARD OF DIRECTORS

- C. Hall Swaim, Esq., president WilmerHale LLP
- Allen L. Snyder III, chairman Northwestern Mutual Life Financial Network
- Garth Greimann, secretary & treasurer Berkshire Partners LLC
- Charles Austin
- Lynn A. Basilio
- American Cancer Society
- Bryan Calder
- U.S. Bank
- John Carberry
- Oppenheimer Multifamily Housing & Healthcare Finance
- Jason A. Elstatiou, MD
- Massachusetts General Hospital
- Neal F. Finnegan
- Clover Capital and Consulting
- Robert Kretschmar
- Global Capital Resources, Inc.
- Tiffany Nagle
- Cullari Communications Global
- C. Kirk Neison
- Avi Nelson
- Dalton A. Skerritt
- Center for the Elimination of Health and Social Inequities and Disparities (CEHSID)

# MEDICAL ADVISORY COMMITTEE

- Richard K. Babayan, MD
- Boston Medical Center
- Glenn J. Bubley, MD
- Beth Israel Deaconess Medical Center
- J. Jacques Carter, MD, MPH
- Beth Israel Deaconess Hospital
- Jason R. Gee, MD
- Lahey Clinic Medical Center
- Philip W. Kantoff, MD
- Dana-Farber/Harvard Cancer Center
- John P. Long, MD
- Newton-Wellesley Hospital
- Tufts University School of Medicine
- Paul Nguyen, MD
- Brigham and Women’s Hospital
- Oliver A. Sartor, MD
- Tulane University School of Medicine
- William U. Shipley, MD
- Massachusetts General Hospital
- Matthew R. Smith, MD
- Massachusetts General Hospital
- Mary-Ellen Taplin, MD
- Dana-Farber Cancer Institute
- Ingolf A. Tuerk, MD, Ph.D.
- St. Elizabeth’s Medical Center

# EXECUTIVE DIRECTOR

- Mark Kennedy, MBA

# DIRECTORS EMERITI

- Arnold Barron
- Bud Collins
- Thomas L. Farmer
- Robert S. Lyons
- Janet McGrail Spillane
- William R. Whitmore